Heart Failure Deep Dive SeriesEp 3 of 4
Semaglutide For Obese Heart Failure Patients

Hosted by Sarah Mitchell & James Carter

0:000:00

More from: Heart Failure Deep Dive Series

How Four Drugs Beat Heart Failure
CardiologyEP 1 OF 4
How Four Drugs Beat Heart Failure

Sarah Mitchell & James Carter

Diabetes Drugs For Stiff Heart Failure
CardiologyEP 2 OF 4
Diabetes Drugs For Stiff Heart Failure

Sarah Mitchell & James Carter

Managing Acute Heart Failure And Cardiogenic Shock
CardiologyEP 4 OF 4
Managing Acute Heart Failure And Cardiogenic Shock

Sarah Mitchell & James Carter

Key Takeaways
  • Obesity is causal in HFpEF via epicardial fat - directly drives cardiac inflammation and fibrosis
  • STEP-HFpEF: semaglutide improved KCCQ +16 pts, 6MWD +21m, weight -13.3% vs placebo; Class IIa ESC recommendation
  • SGLT2 inhibitors and GLP-1 agonists are mechanistically complementary in HFpEF
  • Metabolic cardiomyopathy paradigm: treating the systemic environment, not just the haemodynamics
Save as PDF

Reviewed & published by
Cite This Article

Team TLSFE. Semaglutide for obese heart failure patients. The Life Science Feed. Published June 1, 2026. Updated June 1, 2026. Accessed June 1, 2026. https://thelifesciencefeed.com/cardiology/heart-failure/research/semaglutide-for-obese-heart-failure-patients.

Licence & Rights

© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.

Podcast Disclaimer
Editorial & AI Standards

All content is researched from peer-reviewed, open-access sources — published trial data, clinical guidelines, and regulatory filings. AI tools are used solely to structure and summarise that evidence; no AI-generated conclusions appear without editor verification against the primary source.

Every article is reviewed by a named editor before publication. Source citations are listed in the References section. This content does not represent the views of any pharmaceutical company, medical device manufacturer, or healthcare provider.

References

[1] Kosiborod MN et al. STEP-HFpEF. N Engl J Med. 2023;389:1069-1084

[2] Kosiborod MN et al. STEP-HFpEF-DM. N Engl J Med. 2023;389:1085-1098

[3] Lehrke M et al. SELECT. N Engl J Med. 2023;389:2221-2232

[4] Borlaug BA et al. Heart Failure. 2023;11:1339-1356